management of aids-3[3] (vaibhav)
TRANSCRIPT
-
8/6/2019 Management of Aids-3[3] (Vaibhav)
1/40
-VAIBHAV THAKKAR
FINAL B.D.S
ROLL NO.78
2008-2009
-
8/6/2019 Management of Aids-3[3] (Vaibhav)
2/40
Management of HIV involves both treatment of virus andprevention of opportunistic infections. The aims of HIVtreatment are to reduce the viral load to an undetectable levelfor as long as possible; improve the CD4 count (above 200 cells/mm3) ;increase the quantity and improve qualit y o f lifewithout unacceptable drug related side-effect s o r lifestyle
alteration; and reduce transmission (mother-to-child and post-exposure).
-
8/6/2019 Management of Aids-3[3] (Vaibhav)
3/40
DRUGS
1. Nucleoside Reverse Transcriptase Inhibitors(NRTIs)
Thefirstdrugtoenter clinicalpracticewasZidovudine(ZDV,AZT) in 1987 followingdemonstrationthat itsignificantlyreduced AIDS- associateddiagnosesanddeathsover 6 months.
Other drugs in this class:
Didanosine(ddI),Zalcitaline(ddc),Stavudine(d4T)and Abacavir.
Mechanism of action:NRTIsactthrough intercellularphosphorylationtotriphosphateand incorporate into DNAwheretheyfurther inhibit
lengtheningofcomplementarystrandtotheviral RNAtem late.
-
8/6/2019 Management of Aids-3[3] (Vaibhav)
4/40
Each drug competes with specific nucleoside:
ZDV and d4T with thymidine
3TC and ddC with cytidine
The inclusion of 2 NRTIs remains the cornerstone ofhighly active anti-retroviral therapy(HAART) combination
therapy.
CNS penetration is good with all NRTIs
Resistance occurs to all NRTIs:
Rapid to 3TC
Intermediate for ZDVto a lesser degree for ddI, d4T and Abacavir
-
8/6/2019 Management of Aids-3[3] (Vaibhav)
5/40
Multidrug resistance to all NRTIs is now being
recognized
Dosage of NRTIs:
i. Zidovudine(AZT) : 200mg t.d.s or 250mg b.d
ii. Lamivudine (3TC) : 150mg b.d
iii. Stavudine (d4T) : 30-40mg b.d
iv. Zalcitabine (ddC) : 0.75mg b.d
v. Didanosine(ddI) : 125-200mg b.d
-
8/6/2019 Management of Aids-3[3] (Vaibhav)
6/40
2. Protease Inhibitors (PIs)
The first PI to enter clinical practice was saquinavir (hard
gel formulation) in 1995 followed by indiavir, ritonavir,amprenavir and lopinavir.
Mechanism of Action:PIs prevent post-translational cleavage of polypeptidesinto functional viral proteins. Given with two NRTIs thecombination controls viral replication.
-
8/6/2019 Management of Aids-3[3] (Vaibhav)
7/40
PIs inhibit the p450 cytochrome system giving rise topotential for multiple drug interactions. Adequate
plasma levels are necessary for ,and predictive of,successful treatment. Monitoring the levels(therapeutic drug monitoring) and adjusting the doseaccordingly may be necessary to optimize the antiviral
effect and reduce toxicity.
Dosage ofPIs:
i. SAQUINAVIR: 600mg t.d.s
ii. RITONAVIR: 600mg b.d
iii. INDINAVIR: 800mg t.d.s
-
8/6/2019 Management of Aids-3[3] (Vaibhav)
8/40
3. Non-Nucleoside Reverse Transcriptase Inhibitors(NNRTIs)
There are 3 main NNRTIs:a. Nevirapineb. Delavirdine
c. Efavirenz
Mechanism of Action:Inhibits reverse transcriptase by binding near to theactive enzyme site.
The major disadvantage is potential for development ofcross-resistance to all current drugs in this class througha single mutational change.
-
8/6/2019 Management of Aids-3[3] (Vaibhav)
9/40
Dosage of NNRTIs:
i. Nevirapine: 200mg b.d
ii Delavirdine: 300-400mg t.d.s
4. Newer Drugs
Many drugs are presently in trial or earlier stagesof development are improvements on the currentlyavailable compounds and either have increased
potency, activity against resistant virus or easiercompliance, or are likely to reduce short and longterm complications.
E.g.:- T-20,SCH-C,AMD-3100,S-1360
-
8/6/2019 Management of Aids-3[3] (Vaibhav)
10/40
Table 1. ANTIRETROVIRAL DRUGS:
NRTIsNRTIs PIsPIs NNRTIsNNRTIs OthersOthers
1. Zidovudine(ZDV)1. Zidovudine(ZDV) SaquinavirSaquinavir NevirapineNevirapine HydroxyureaHydroxyurea
2. Lamivudine(3TC)2. Lamivudine(3TC) RitonavirRitonavir EfavirenzEfavirenz TT--2020
3. Stavudine(d4T)3. Stavudine(d4T) IndinavirIndinavir DelavirdineDelavirdine FusionFusionInhibitorsInhibitors
4. Zalcitabine(ddC)4. Zalcitabine(ddC) LopinavirLopinavir
5. Didanosine(ddI)5. Didanosine(ddI) NelfinavirNelfinavir
-
8/6/2019 Management of Aids-3[3] (Vaibhav)
11/40
Table 2. ANTI-RETROVIRAL DRUG SIDE EFFECTS:
Drug ClassDrug Class SideSide--EffectsEffects
NRTIsNRTIs
Peripheral neuropathyPeripheral neuropathy AnaemiaAnaemia
MyopathyMyopathy
CardiomyopathyCardiomyopathy
Hepatic SteatosisHepatic Steatosis Lactic AcidosisLactic Acidosis
PancreatitisPancreatitis
Extremity fat lossExtremity fat loss
-
8/6/2019 Management of Aids-3[3] (Vaibhav)
12/40
PIsPIs Fat redistributionFat redistribution
HyperlipidaemiaHyperlipidaemiaCoronary artery diseaseCoronary artery disease
Insulin resistanceInsulin resistance
HyperglycemiaHyperglycemia
NRTIsNRTIs RashRash
CNS sideCNS side--effects likeeffects likedizziness,insomnia,vivid dreamsdizziness,insomnia,vivid dreams
Stevens Johnson SyndromeStevens Johnson Syndrome
HAARTHAART Bone DemineralisationBone Demineralisation
-
8/6/2019 Management of Aids-3[3] (Vaibhav)
13/40
Treatment
The nave patient
The decision to start therapy is major one.It is dependent upon:
Symptoms status of patient
CD4 count
Viral load (VL)
Wishes of the patient
-
8/6/2019 Management of Aids-3[3] (Vaibhav)
14/40
Currently, there is no clear move to delay therapy untilthere are clinical or immunological indications to
commence and not just the basis of a high VL.
Table 3. INDICATION TO START HAART
CD4 Count (cells/mmCD4 Count (cells/mm33 )) DecisionDecision
Seroconversion > 350Seroconversion > 350 Monitor 2 monthlyMonitor 2 monthly
200200--350350 Monitor/Drugs therapyMonitor/Drugs therapybased on VLbased on VL
< 200< 200 Recommended drug therapyRecommended drug therapy
The risk of HIV-related opportunistic infection increasesand treatment is less effective when CH4 count is < 200cells/mm3 .Also, higher the VL, faster the CD4 count falls.
-
8/6/2019 Management of Aids-3[3] (Vaibhav)
15/40
A potent combination (HAART:Highly Active Antiretroviral Therapy) should always be
used.
Table 4. * COMBINATION TREATMENTS FOR THE NAVE PATIENTS
Standard ( 2NRTIs + PI / NNRTIs)
2NRTIs d4T + 3TC ZDV + 3TC
d4T + ddC ZDV + ddI
PI / NNRTIs Saquinavir Lopinavir
Indinavir Nevirapine
Ritonavir
Nelfinavir
Other Regimens
Equal Potency ZDV + 3TC + Abacavir
NNRTI + PI + NRTI
2 PI + 2NRTI
Uncertain Potency NNRTI + PI
2 NNRTI + 2 NRTI
-
8/6/2019 Management of Aids-3[3] (Vaibhav)
16/40
When starting treatment certain factors need to beconsidered.
Table 5. Factors to be Considered:
Ease of complianceFit of drug regimen around patients lifestyleWishes of the patientStages of diseasesCo-existing / past medical historyPossibility of side-effects
Potential for drug interactionCNS penetrationPossibility of acquisition of resistance virusAntagonistic NRTI combinations (ZDV / d4T and ddC /3TC)
-
8/6/2019 Management of Aids-3[3] (Vaibhav)
17/40
Despite careful and appropriate choice of HAART, thechances of a VL of < 50 copies / mm3 at 24 weeks areonly approximately 75%.
Factors that reduce the probability of achievingprolonged viral suppression are:
1.Suboptimal potency of the regimen
2. High baseline VL
3. CD4 count of < 200 / mm3
4. Poor adherence
5. Prior exposure to antiretroviral drugs
6. Resistance virus
-
8/6/2019 Management of Aids-3[3] (Vaibhav)
18/40
MEDICAL INTERVENTION FOR MANAGEMENT OFHIV:
1) Anti- retroviral therapy
2) Prophylactic therapy against Pneumocystis Cariniiand Cereberal Toxoplasmosis
3) Ancillary care , including earlier diagnosis and
better treatment of opportunistic infections.
-
8/6/2019 Management of Aids-3[3] (Vaibhav)
19/40
ENHANCING THE IMMUNE SYSTEM
In the knowledge that HAART alone will not cure thepatient of HIV, focus has now turned towards possibilityof bolstering immune system with the hope thatvirological control without drugs may be achievable. Thiscan be achieved by:
o STI: Structured Therapeutic Interruption
o Direct anti-HIV cytotoxic T-cell stimulation through
immunisation with viral proteins.
Whether either approach will prove to be beneficial inlong term is unknown.
-
8/6/2019 Management of Aids-3[3] (Vaibhav)
20/40
IMPACT OF HIV AND AIDS
Epidemiologists anticipated that AIDS would decimate
the workforce population in dentistry.
Public alarm was intense when a Florida dentist withclinical AIDS transmitted his unique strain of HIV to 6patients in his large dental practice. This could havebeen prevented by conscientious use of infectioncontrol procedures.
OSHA(Occupational Safety and Health Administration)regulations have provided an intense impetus tostrengthen and control aseptic standards in all healthcare disciplines.
-
8/6/2019 Management of Aids-3[3] (Vaibhav)
21/40
Infection control is now accepted as a standard of careby dentists
Infection control programmes,such as those by CDC (
Centres for Diseases Control and Prevention) and ADAare designed to protect patients and personnel
Exposure is defined in the OSHA regulations as:-specificeye,mouth,other mucous membrane, on-intact skin, orparental contact with blood or OPIM (Other PotentiallyInfectious Materials) that results from performance of anemployees duties.
-
8/6/2019 Management of Aids-3[3] (Vaibhav)
22/40
Only in dentistry is saliva considered a potentiallyinfectious material because oral manipulations and dentaltreatments routinely cause saliva to become
contaminated with patients blood .In dental practice, allpatients must be treated with standard precautions toreduce the risk of disease transmission.
Dentists should obtain and read a copy of the FinalOSHA Rule on Blood borne Pathogens.
-
8/6/2019 Management of Aids-3[3] (Vaibhav)
23/40
HIV RISKS FOR CLINICAL PERSONNEL
Testing for evidence of prior HIV infection at time ofexposure was not commonly performed in dentistry until1990s.
HIV infection has developed in a nurse and a technician
spattered with HIV- infected blood. Other medicalpersonnel have acquired HIV infections related to spatterof infected blood to their non-intact skin.
Personal are required to protect eyes,mucosa,skin andhands from spatter and direct contact with blood andblood contamination body fluids during treatment of allpatients.
-
8/6/2019 Management of Aids-3[3] (Vaibhav)
24/40
Precaution also must be made to minimize risks ofinjuries with sharp instructions.
HIV is killed by all methods of sterilization. When used
properly all disinfectants (except some quaternaryammonium compounds) are said to inactivate HIV in lessthan 2 mins.
-
8/6/2019 Management of Aids-3[3] (Vaibhav)
25/40
EXPOSURE ASSESSMENT PROTOCOL
Dental students are required to follow some exposureincident protocol plan as dental employees, in case of anaccidental exposure.
If possible, patients potential to transmit and the
students susceptability is determined.
The attending physician who helps with thesedeterminations provides anti-HIV testing and counseling.
-
8/6/2019 Management of Aids-3[3] (Vaibhav)
26/40
HIV INFECTION CONTROL
It can be described under 3 headings:
1. Universal Precautions2. Measures at time of Surgery3. Measures for Health Care Workers (HCWs)
1.Universal Precautions
Infection control strategies reduce the risk oftransmission of infectious diseases.
All infected patients cannot be identified on the basis ofmedical history, examination and lab investigations,hence,philosophy is to consider all patients infected andfollow certain basic infection control procedures referred
to as universal precautions.
-
8/6/2019 Management of Aids-3[3] (Vaibhav)
27/40
Universal precautions for dental team entail:
i) Employment of various personal protectivebarrier techniques such as:-
Gowns Face masks Protective eyewear Gloves Handwashing and care of hands Clinical attire Head caps No refreshments in clinical areas Protective over-garments
-
8/6/2019 Management of Aids-3[3] (Vaibhav)
28/40
ii) Disposal of clinical waste
iii) Needle disposal
iv) Precautions to avoid Injury Exposure
v) Contaminated items to be discarded;protected by disposable covers; or removed,cleaned and sterilized.
-
8/6/2019 Management of Aids-3[3] (Vaibhav)
29/40
2. Measures at Time of Surgery
A protocol to be followed in OT. Special precautions: when dealing with HIV positive or
high risk patients, special precautions are to be taken:-
i) In operation theaterii) For personneliii) Surgery techniques ( no touch technique)iv) At end of surgeryv) OT waste disposal
vi) Reusable instruments to be autoclaved and washedvii) Non-Autoclavable to be disinfected in 2 %
Glutraldehyde solutionviii) Laboratory specimensix)Equipments and surfaces
-
8/6/2019 Management of Aids-3[3] (Vaibhav)
30/40
3. Measures for Health Care Workers(HCWs)
Transmission of HIV infection from patient to HCW hasbeen reported.
The risk of acquiring HIV three needle stick injury isapprox.0.4% and three exposure of mucous membrane is0.04%
Needle Stick Injury is the most common cause of
contracting HIV infection in HCWs.
The risk of acquiring HIV infection can be negligible ,ifthe HCWs observe adequate safety measures andobserve universal safety precaution mentioned above.
-
8/6/2019 Management of Aids-3[3] (Vaibhav)
31/40
*NEEDLE STICK INJURY
Measures forPreventions:
1.Ensuring needles and surgical blades are sheathed /covered, when not in use
2.Keeping full control of sharp instruments and retain fullconcentration while handling it.
3.Keeping gloved fingers behind the edge of blades or
points of needles.
4.Adequate retraction of tissues
-
8/6/2019 Management of Aids-3[3] (Vaibhav)
32/40
5.Placing needles in sharp safe box
6.Taking care when clearing away surgical sharps
7.Over-gloving or using double gloves,wheneverindicated.
*POST ACCIDENTAL MANAGEMENT
Measures to be taken are:
a) Remove gloves
b) Wash the site of injury under running water withsoap and water
c) Avoid scrubbing and encourage bleeding and then
protect
-
8/6/2019 Management of Aids-3[3] (Vaibhav)
33/40
d) It is controversial whether or not to apply antisepticprecautions
e) Inform the patient about incident
f) Usually,it is necessary to take blood samples of both
patient and the injured person and tested for HIV.
-
8/6/2019 Management of Aids-3[3] (Vaibhav)
34/40
In case, patient is seropositive, has AIDS, or refusesthe tests, the HCWs should be :
i. Counseled about risk of infection and evaluated
clinically and serologically as soon as possible.
ii. A baseline HIV test should be carried.
iii.Adviced to report for any febrile illness that mayoccur within 12 weeks of exposure.
-
8/6/2019 Management of Aids-3[3] (Vaibhav)
35/40
iv. HIV test should then should be repeated approx. 6 to12 weeks after exposure
v. Advice to follow the steps to prevent transmission ofHIV.
vi. Advice regarding domestic relationships andprocedures at workplace
-
8/6/2019 Management of Aids-3[3] (Vaibhav)
36/40
-
8/6/2019 Management of Aids-3[3] (Vaibhav)
37/40
Table. 6 HIV,PEP for HCWs
TypeType DrugsDrugs RegimenRegimen
Basic (28 days)Basic (28 days) ZidovudineZidovudine ++LamivudineLamivudine
600mg/ day +600mg/ day +150mg/ day150mg/ day
ExpandedExpanded(28 days)(28 days)
As above +As above +
IndinavirIndinavir
oror
NelfinavirNelfinaviroror
NevirapineNevirapine
800mg800mg--8 hourly,8 hourly,
750mg750mg t.d.st.d.s,,
200mg200mg b.db.d..
-
8/6/2019 Management of Aids-3[3] (Vaibhav)
38/40
The first dose should be given as soon as possible.However, protection is not absolute and healthcare
workers have been reported to seroconvert despite takinga full course of three drugs started within hours ofexposure.
PEP is also being used for non-occupational settings
such as condom breakage in HIV serodiscordant partners,victims of rape, relapses in injecting drug users, andsharps-related home exposures in families of HIVpatients.
As for occupation PEP, a careful risk assessment bemade. Benefits will be greatest in those presenting early,where the risk of transmission is high and whereadherence is likely.
-
8/6/2019 Management of Aids-3[3] (Vaibhav)
39/40
References
1) Textbook of ORAL MEDICINE Anil GovindraoGhom.
2) Davidsons Principles & Practice ofMedicine
3) Barlett J.G Medical Management of HIV infection www.hopkins-aids.edu
4) Medicine for Students ASPI . F . GOLWALLA
5) Textbook of Oral &Maxillofacial Surgery NeelimaAnil Malik.
6) Sturdevants Art & Science of Operative Dentistry.
-
8/6/2019 Management of Aids-3[3] (Vaibhav)
40/40